AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17621379 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained CMHN providing psychosocial intervention (PSI)
Number of subjects: 113
Study 17621379 — intervention group
Group type: COMPARATOR
Intervention: Usual practice CMHN
Number of subjects: 113
Study 15966887 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Gum Care
Number of subjects: 110
Study 15966887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentadent P
Number of subjects: 110
Study 15966887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15966887 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Gum Care and Mentadent P
Number of subjects: 110
Study 12030915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% testosterone gel preparation
Number of subjects: 28
Study 9793615 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl (Praxilene)
Number of subjects: 30
Study 8293835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive vaginal moisturizer
Number of subjects: 30
Study 8293835 — intervention group
Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 30
Study 3276526 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose surfactant (120 mg/kg)
Number of subjects: 46
Study 3276526 — intervention group
Group type: COMPARATOR
Intervention: Low-dose surfactant (60 mg/kg)
Number of subjects: 46
Study 1103113 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone 450 mg daily
Number of subjects: 14
Study 1103113 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg daily
Number of subjects: 14
Study 31364144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Sambucus nigra, Zinc, Tyndallized Lactobacillus acidophilus (H122), Arabinogalactans, vitamin D, vitamin E, vitamin C)
Number of subjects: 198
Study 31364144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Group 2)
Number of subjects: 198
Study 31364144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Group 2 and 3)
Number of subjects: 198
Study 31364144 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for rhinitis and OME (Control group)
Number of subjects: 198
Study 28715908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment (N=36)
Number of subjects: 66
Study 28715908 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (TMS) concurrent with fMRI (N=17 subset of prolonged exposure group)
Number of subjects: 66
Study 28715908 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (N=30)
Number of subjects: 66
Study 24728329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) at doses 10, 15, 20, and 25 mg weekly
Number of subjects: 47
Study 24728329 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (SC MTX) administered via auto-injector (MTXAI) at doses 10, 15, 20, and 25 mg weekly
Number of subjects: 47
Study 24728329 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (SC MTX)
Number of subjects: 47
Study 24337328 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Emotion-Oriented Care (IEOC)
Number of subjects: 16
Study 24337328 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 16
Study 20538128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 913
Study 18580406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise program (walking 10,000 steps, three times a week)
Number of subjects: 34
Study 16884344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (n = 25) - topical application of lavender, clary sage, and rose in almond oil
Number of subjects: 67
Study 16884344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20) - almond oil only
Number of subjects: 67
Study 16884344 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 22) - no treatment
Number of subjects: 67
Study 14626377 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (HT)
Number of subjects: 0
Study 14626377 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hormone therapy (HT)
Number of subjects: 0
Study 14626377 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary interruption of hormone therapy (HT) before mammography
Number of subjects: 0
Study 10805048 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurement device (OMRON)
Number of subjects: 622
Study 10805048 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 622
Study 8636588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (computer-generated drug list to cancel or renew RXs)
Number of subjects: 348
Study 8636588 — intervention group
Group type: COMPARATOR
Intervention: Control group (could not cancel outpatient drugs, wrote all medications on individual prescriptions)
Number of subjects: 348
Study 1390495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A 5 mg/kg/day
Number of subjects: 23
Study 1390495 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 1 g intravenous boluses monthly
Number of subjects: 23
Study 3893815 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg b.d.
Number of subjects: 18
Study 3893815 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg b.d.
Number of subjects: 18
Study 3893815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29044521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraper (TS)
Number of subjects: 18
Study 29044521 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush (TB)
Number of subjects: 18
Study 27682493 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound monoammonium glycyrrhizinate combined with dandelion (TCM group)
Number of subjects: 80
Study 27682493 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 80
Study 24666618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 7595
Study 24666618 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 7595
Study 24666618 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body weight
Number of subjects: 7595
Study 24666618 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body weight in patients with NODM
Number of subjects: 7595
Study 24666618 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body weight and NODM risk
Number of subjects: 7595
Study 22659151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed power training for 12 weeks
Number of subjects: 37
Study 22659151 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (DT) for 6 weeks after training
Number of subjects: 37
Study 22659151 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 37
Study 21038754 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (continuous wave mode, 5 W)
Number of subjects: 15
Study 21038754 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (pulsed char-free mode)
Number of subjects: 15
Study 21038754 — intervention group
Group type: COMPARATOR
Intervention: Diode laser (5.12 W, pulsed mode)
Number of subjects: 15
Study 18625920 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) behaviors
Number of subjects: 287
Study 18625920 — intervention group
Group type: COMPARATOR
Intervention: Older physicians
Number of subjects: 287
Study 18625920 — intervention group
Group type: COMPARATOR
Intervention: Physicians in health maintenance organization settings
Number of subjects: 287
Study 18625920 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer visit duration
Number of subjects: 287
Study 18625920 — intervention group
Group type: EXPERIMENTAL
Intervention: SPs making general medication requests
Number of subjects: 287
Study 18625920 — intervention group
Group type: EXPERIMENTAL
Intervention: SPs making brand-specific medication requests
Number of subjects: 287
Study 16273800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Number of subjects: 0
Study 16273800 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified versions of the FIQ (1997 and 2002)
Number of subjects: 0
Study 16273800 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated versions of the FIQ
Number of subjects: 0
Study 11822921 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of hyaluronate sodium at a concentration of 10 mg/mL
Number of subjects: 120
Study 11822921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti‐inflammatory drugs (NSAIDs) (75 mg of diclofenac and 200 microg of misoprostol) and hyaluronate sodium
Number of subjects: 120
Study 11822921 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs and placebo (2 mL of isotonic sodium chloride solution [saline])
Number of subjects: 120
Study 11822921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose and saline)
Number of subjects: 120
Study 9894580 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 9894580 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 0
Study 8619109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative internal brachytherapy (two alternative doses)
Number of subjects: 0
Study 2203305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g daily for 14 days)
Number of subjects: 36
Study 2203305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2203305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 36
Study 7212794 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood (WB)
Number of subjects: 28
Study 7212794 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cells (PRBC)
Number of subjects: 28
Study 7212794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WB and PRBC)
Number of subjects: 28
Study 31995811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and varenicline administration during abstinence
Number of subjects: 44
Study 31995811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31995811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 44
Study 31995811 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline administration
Number of subjects: 44
Study 30839408 — intervention group
Group type: EXPERIMENTAL
Intervention: GALILEI Scheimpflug camera
Number of subjects: 50
Study 30839408 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GALILEI and Pentacam
Number of subjects: 50
Study 28960283 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental videos (role competency and social inclusion)
Number of subjects: 295
Study 28960283 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 295
Study 28960283 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental videos and control
Number of subjects: 295
Study 28459236 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day sugarcane bagasse plus conventional treatment
Number of subjects: 196
Study 28459236 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus conventional treatment
Number of subjects: 196
Study 24481688 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (220 μg folic acid, 1.1 mg vitamin B2, 0.73 mg B6, 1.2 μg B12, 130 mg calcium)
Number of subjects: 250
Study 24481688 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (control group)
Number of subjects: 250
Study 24481688 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin supplementation
Number of subjects: 250
Study 24481688 — intervention group
Group type: COMPARATOR
Intervention: B vitamin supplementation and Calcium only (control)
Number of subjects: 250
Study 21272705 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% protein condition
Number of subjects: 18
Study 21272705 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% protein condition
Number of subjects: 18
Study 21272705 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein condition
Number of subjects: 18
Study 21272705 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% protein condition
Number of subjects: 18
Study 21272705 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% protein condition
Number of subjects: 18
Study 21272705 — intervention group
Group type: COMPARATOR
Intervention: All protein conditions (10% to 30%)
Number of subjects: 18
Study 19953989 — intervention group
Group type: EXPERIMENTAL
Intervention: RHEOSORBILACTUM
Number of subjects: 60
Study 19953989 — intervention group
Group type: COMPARATOR
Intervention: VENOFUNDIN
Number of subjects: 60
Study 16769942 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 28
Study 16769942 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study 15284736 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Number of subjects: 1000
Study 15284736 — intervention group
Group type: COMPARATOR
Intervention: 2 x 1 pocket technique
Number of subjects: 1000
Study 11688901 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 156
Study 11688901 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 156
Study 11688901 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 156
Study 11688901 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 156
Study 11688901 — intervention group
Group type: COMPARATOR
Intervention: Josamycin
Number of subjects: 156
Study 9206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 74
Study 9206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 74
Study 7697694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg loperamide oxide
Number of subjects: 230
Study 7697694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg loperamide oxide
Number of subjects: 230
Study 7697694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 7697694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg loperamide oxide
Number of subjects: 230
Study 7697694 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide
Number of subjects: 230
Study 3308343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 90
Study 3308343 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 90
Study 31898006 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 2152
Study 31898006 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience EES
Number of subjects: 2152
Study 29476810 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 246
Study 29476810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal ovarian needle drilling (TND)
Number of subjects: 246
Study 27931564 — intervention group
Group type: EXPERIMENTAL
Intervention: New systematic communication approach between medical staff and patients' relatives
Number of subjects: 291
Study 27931564 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention period (2007-2012)
Number of subjects: 291
Study 27931564 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention period (2013-2015)
Number of subjects: 291
Study 24742970 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/day)
Number of subjects: 155
Study 24742970 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 155
Study 24742970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aliskiren (150 mg/day) and losartan (100 mg/day)
Number of subjects: 155
Study 23806094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention (personalized skin cancer education through the mail)
Number of subjects: 0
Study 23806094 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic skin cancer information materials)
Number of subjects: 0
Study 21679006 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/dienogest
Number of subjects: 29
Study 21679006 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol/levonorgestrel
Number of subjects: 29
Study 19049700 — intervention group
Group type: EXPERIMENTAL
Intervention: GOP‐A‐Flu (test)
Number of subjects: 24
Study 19049700 — intervention group
Group type: COMPARATOR
Intervention: Tamiflu (reference)
Number of subjects: 24
Study 16818983 — intervention group
Group type: EXPERIMENTAL
Intervention: Static plate construct
Number of subjects: 21
Study 16818983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic plate constructs
Number of subjects: 21
Study 16818983 — intervention group
Group type: COMPARATOR
Intervention: All tested anterior cervical plating systems
Number of subjects: 21
Study 12699022 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention group
Number of subjects: 158
Study 12699022 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 158
Study 10886592 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐568 (100 mg)
Number of subjects: 21
Study 10886592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8933119 — intervention group
Group type: COMPARATOR
Intervention: Bulgofilus (fermented milk enriched with Lactobacillus bulgaricus)
Number of subjects: 14
Study 8933119 — intervention group
Group type: COMPARATOR
Intervention: Ofilus (fermented milk containing Lactobacillus acidophilus and Bifidobacterium sp.)
Number of subjects: 14
Study 8933119 — intervention group
Group type: COMPARATOR
Intervention: Traditional yoghurt
Number of subjects: 14
Study 8933119 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (control)
Number of subjects: 14
Study 1559738 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg twice daily
Number of subjects: 164
Study 1559738 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 500 mg twice daily
Number of subjects: 164
Study 1559738 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 164
Study 1559738 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 164
Study 3902362 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 (0.5 mg) administered every 4 h via nasogastric tube
Number of subjects: 90
Study 3902362 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 4 h via nasogastric tube
Number of subjects: 90
Study 31432072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic whole-grain dietary pattern (WG)
Number of subjects: 80
Study 31432072 — intervention group
Group type: COMPARATOR
Intervention: Dietary pattern high in refined grains and added sugars (RG)
Number of subjects: 80
Study 30043079 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g/day)
Number of subjects: 34
Study 30043079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study 26111826 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-fingolimod 0.5 mg
Number of subjects: 1027
Study 26111826 — intervention group
Group type: COMPARATOR
Intervention: IFN-switch (switched from interferon β‐1a to fingolimod)
Number of subjects: 1027
Study 24588989 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 50
Study 24588989 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic laparoscopy (Control)
Number of subjects: 50
Study 22910291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 treatment for 1 year
Number of subjects: 21
Study 21047591 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer with a 6 year interval
Number of subjects: 50
Study 17969401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (doxorubicin+paclitaxel)
Number of subjects: 0
Study 17969401 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy with aromatase inhibitors (anastrazole or exemestane)
Number of subjects: 0
Study 15454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist exercise recommendation only
Number of subjects: 450
Study 15454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist exercise recommendation plus referral to an exercise specialist
Number of subjects: 450
Study 15454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of exercise recommendation
Number of subjects: 450
Study 15454357 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study 11793169 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg/day, daily; n = 23)
Number of subjects: 72
Study 11793169 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (200 mg/day, 14 days per 3 months; n = 25)
Number of subjects: 72
Study 11793169 — intervention group
Group type: COMPARATOR
Intervention: Calcium lactate (2 g/day, daily; n = 24)
Number of subjects: 72
Study 9672958 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus ongoing consultation and networking for clinic team leaders (I)
Number of subjects: 44
Study 9672958 — intervention group
Group type: COMPARATOR
Intervention: Standard care without additional training (C)
Number of subjects: 44
Study 8005130 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 360 mg.day-1
Number of subjects: 1757
Study 8005130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1757
Study 2679444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (2 x 2.5 mg/week)
Number of subjects: 30
Study 2679444 — intervention group
Group type: COMPARATOR
Intervention: Danazol (3 x 200 mg/day)
Number of subjects: 30
Study 2679444 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day intranasally)
Number of subjects: 30
Study 59517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishydroxycoumarin
Number of subjects: 54
Study 59517 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon
Number of subjects: 54
Study 59517 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 54